Abstract
The antineoplastic agent’s cisplatin and carboplatin are widely used as they are highly effective. Unfortunately, ototoxicity is a frequently encountered side effect of platinum-based chemotherapy. Clinically, patients generally develop a progressive, bilateral, and irreversible sensorineural hearing loss. With rising cancer survival rates, a greater proportion of patients are living with the side effects of their chemotherapy treatments. Consequently, the quality of life of cancer survivors has now become a major concern for clinicians. Various classification systems are currently available to grade side effects and provide a guideline for subsequent treatments. An extensive review of the literature revealed that a variety of criteria are used worldwide for grading platinum-induced hearing loss in children and adults, including the National Cancer Institute criteria, Brock’s grading system, the American Speech-Hearing-Language Association criteria, the World Health Organization criteria, the Pediatric Oncology Group criteria, and the Muenster classification. Less commonly used criteria include the Chang classification, the Functional Hearing Loss scale, the HIT system (German Hirntumor study grading system), and most recently, the International Society of Pediatric Oncology Boston ototoxicity grading scale. The objective of this review is to evaluate the commonly used ototoxicity criteria and discuss their benefits and limitations.
Similar content being viewed by others
References
National Institutes of Health (NIH) (2013). Fact sheet—cancer. http://report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=75. Accessed 21 Mar 2016
Helt-Cameron J, Allen JP (2009) Cisplatin ototoxicity in children: implications for primary care providers. Pediatr Nurs 35:121–127
Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33:9–23
Rybak LP, Mukherjea D, Jajoo S, Ramkumar V (2009) Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med 219:177–186
Rybak LP (2007) Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr Opin Otolaryngol Head Neck Surg 15:364–369
Herrmann J, Yang EH, Iliescu CA et al (2016) Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. Circulation 133:1272–1289
Ciccone MM, Cortese F, Pinto M et al (2012) Endothelial function and cardiovascular risk in patients with idiopathic sudden sensorineural hearing loss. Atherosclerosis 225:511–516
Carleton BC, Ross CJ, Pussegoda K et al (2014) Genetic markers of cisplatin-induced hearing loss in children. Clin Pharmacol Ther 96:296–298
Xu H, Robinson GW, Huang J et al (2015) Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet 47:263–266
Lanvers-Kaminsky C, Sprowl JA, Malath I et al (2015) Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics 16:323–332
Schroeder L, Petrou S, Kennedy C et al (2006) The economic costs of congenital bilateral permanent childhood hearing impairment. Pediatrics 117:1101–1112
Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181
National Institutes of Health (NIH) (2013). Adverse Events/CTCAE. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 21 Mar 2016
da Silva AM, Latorre MRD, Cristofani LM et al (2007) The prevalence of hearing loss in children and adolescents with cancer. Braz J Otorhinolaryngol 73:608–614
Neuwelt EA, Brock P (2010) Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 28:1630–1632
Knight KR, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23:8588–8596
Chang KW, Chinosornvatana N (2010) Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 28:1788–1795
Knight KR, Kraemer DF, Winter C et al (2007) Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 25:1190–1195
Bertolini P, Lassalle M, Mercier G et al (2004) Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26:649–655
Brock PR, Bellman SC, Yeomans EC et al (1991) Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 19:295–300
Orgel E, Jain S, Ji L et al (2012) Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. Pediatr Blood Cancer 58:953–958
Marina N, Chang KW, Malogolowkin M et al (2005) Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children’s Oncology Group Study. Cancer 104:841–847
Schultz C, Goffi-Gomez MVS, Liberman PHP et al (2009) Report on hearing loss in oncology. Braz J Otorhinolaryngol 75:634–641
Kushner BH, Budnick A, Kramer K et al (2006) Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 107:417–422
American Speech-Language-Hearing Association (1994) Audiologic management of individuals receiving cochleotoxic drug therapy [Guidelines]. http://www.asha.org/policy. Accessed 21 Mar 2016
Dutta A, Venkatesh MD, Kashyap RC (2005) Study of the effects of chemotherapy on auditory function. Indian J Otolaryngol Head Neck Surg 57:226–228
World Health Organization (1991). Report of the informal working group on prevention of deafness and hearing impairment, programme planning. WHO/PDH/91.1
Smith AW (2001) WHO activities for prevention of deafness and hearing impairment in children. Scand Audiol Suppl 53:93–100
Zuur CL, Simis YJ, Lansdaal PE et al (2007) Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 25:3759–3765
Stöhr W, Langer T, Kremers A et al (2005) Cisplatin-induced ototoxicity in osteosarcoma patients: a report from the late effects surveillance system. Cancer Invest 2005(23):201–207
Lee AW, Yau TK, Wong DHM et al (2005) Treatment of stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation. Int J Radiat Oncol Biol Phys 63:1331–1338
Huang E, Teh BS, Strother DR (2002) Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 52:599–605
Schmidt CM, Bartholomäus E, Deuster D, Heinecke A, Dinnesen AG (2007) The “Muenster classification” of high frequency hearing loss following cisplatin chemotherapy. HNO 55:299–306
Lafay-Cousin L, Purdy E, Huang A et al (2013) Early cisplatin induced ototoxicity profile may predict the need for hearing support in children with medulloblastoma. Pediatr Blood Cancer 60:287–292
Katzenstein HM, Chang K, Krailo M et al (2009) Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer 115:5828–5835
Spracklen TF, Whitehorn H, Vorster AA, Ramma L, Dalvie S, Ramesar RS (2014) Genetic variation in Otos is associated with cisplatin-induced ototoxicity. Pharmacogenomics 15:1667–1676
Peleva E, Emami N, Alzahrani M et al (2014) Incidence of platinum-induced ototoxicity in pediatric patients in Quebec. Pediatr Blood Cancer 61:2012–2017
Lewis MJ, DuBois SG, Fligor B et al (2009) Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 52:387–391
Lannering B, Rutkowski S, Doz F et al (2012) Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 trial. J Clin Oncol 30:3187–3193
Sakamoto M, Kaga K, Kamio T (2000) Extended high-frequency ototoxicity induced by the first administration of cisplatin. Otolaryngol Head Neck Surg 122:828–833
Brock PR, Knight KR, Freyer DR et al (2012) Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol 30:2408–2417
Hagleitner MM, Coenen MJ, Patino-Garcia A et al (2014) Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts. PLoS One 9:e115869
Bass JK, Huang J, Onar-Thomas A et al (2014) Concordance between the chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatr Blood Cancer 61:601–605
Gurney JG, Bass JK (2012) New International Society of Pediatric Oncology Boston Ototoxicity Grading Scale for pediatric oncology: still room for improvement. J Clin Oncol 30:2303–2306
Abujamra AL, Escosteguy JR, Dall’Igna C et al (2013) The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy. Pediatr Blood Cancer 60:474–478
Davis H, Silverman SR (1978) Hearing and deafness. Holt, Rinehart & Winston, New York
Lanvers-Kaminsky C, Krefeld B, Dinnesen AG et al (2006) Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer 47:183–193
Qaddoumi I, Bass JK, Wu J et al (2012) Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30:1034–1041
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Waissbluth, S., Peleva, E. & Daniel, S.J. Platinum-induced ototoxicity: a review of prevailing ototoxicity criteria. Eur Arch Otorhinolaryngol 274, 1187–1196 (2017). https://doi.org/10.1007/s00405-016-4117-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-016-4117-z